Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
NCT ID: NCT01935427
Last Updated: 2015-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2013-09-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Healthy human subjects will undergo progressive reduction in central blood volume to the point of hemodynamic instability (defined by a precipitous fall in systolic blood pressure (SBP) below 70 mmHg and/or voluntary subject termination due to discomfort (such as sweating, nausea, or dizziness) to validate the following hypotheses:
The CypherOx CRI system will A. Trend intravascular volume changes (hemorrhage) B. Trend stroke volume changes and C. The CRI trend value is not relative to an initial CRI reading, instead it is an actual CRI trend value that does not require calibration or being placed during normal physiological conditions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compensatory Reserve Index as a Hemodynamic Status Evaluation Tool in Patients
NCT02701725
Comparison of Compensatory Reserve Index to Changes in Stroke Volume and Intravascular Volume
NCT02980471
Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery
NCT01866657
Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates
NCT03446326
Evaluation of Capillary Refill Index
NCT04144166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Volunteer test subjects
Healthy volunteer with no cardiovascular disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 to 55 yr.
* Normal clinical results from a Medical History and Physical form DD 2807-1
* Military or civilian.
* Documentation of a negative pregnancy test within 24 hours prior to each study period, if necessary.
* Not obese, as defined by body mass index (BMI) \< 30, unless individual is athletic (BMI may not be the best method of assessing obesity in athletic individuals). BMI is calculated as the weight in kilograms divided by the square of the height in meters.
Exclusion Criteria
* Individuals taking prescription drugs, non-prescription drugs or herbal medicines known to alter autonomic function unless cleared by the Medical Screener.
* Subjects using prescription medications within 30 days before initiation of the experiments unless cleared by the Medical Screener.
* Subjects with a history of alcohol or drug abuse which inhibits the subject's ability to complete this study.
* Smokers.
* Subjects with signs of cardiovascular abnormalities (e.g., hypertension (\> 140/90), autonomic dysfunction (Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension), fainting disorder, etc.).
* Subjects with respiratory illnesses (e.g., asthma, Chronic Obstructive Pulmonary Disease, Reactive Airway Disease, etc.).
* Subjects with a history of anaphylaxis.
* Subjects with allergies to medications not cleared by the Medical Screener. Individuals reporting a history of pre-syncopal/syncopal episodes or orthostatic hypotension.
* Subjects with a history or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs.
* Individuals taking prescription medications for hypertension (high blood pressure). (l) Individuals with known or suspected abdominal hernias
* Pregnancy, trying to become pregnant, or breastfeeding
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Flashback Technologies
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victor A Convertino, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
US Army Institute of Surgical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
US Army Institute of Surgical Research
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRIV2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.